Online inquiry

IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7244MR)

This product GTTS-WQ7244MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets STAB1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_015136.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23166
UniProt ID Q9NY15
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7244MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15929MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ7466MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ14411MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ8745MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4792MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ12137MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ14406MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ11623MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW